Evaluation of a novel reporter virus neutralization test for serological diagnosis of Zika and Dengue virus infection

Chao Shan, Daniel A. Ortiz, Yujiao Yang, Susan J. Wong, Laura D. Kramer, Pei-Yong Shi, Michael J. Loeffelholz, Ping Ren

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Currently, the laboratory diagnosis of Zika virus (ZIKV) infection is primarily through the detection of ZIKV RNA or antibodies against ZIKV proteins. The detection of viral RNA is highly sensitive and specific, but periods of viremia and viruria are brief, limiting the utility of ZIKV RNA assays. Instead, most ZIKV infections are diagnosed serologically, using an IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) for screening, followed by a confirmatory plaque reduction neutralization test (PRNT). Typical turnaround times vary, due to assay incubation periods and a lack of clinical laboratories performing these tests. Recently, a novel luciferase-ZIKV-and-dengue virus (DENV)-based serological assay, which considerably improves the turnaround times and throughput for ZIKV diagnosis, was described. Using the traditional PRNT as a reference method, we evaluated the performance characteristics of the reporter virus neutralization test (RVNT) with 258 clinical serum specimens. The ZIKV RVNT produced primary ZIKV screening and secondary confirmation results in 4 days, with 100% reproducibility. As a screening assay, the ZIKV RVNT displayed excellent diagnostic accuracy, sensitivity, and specificity of 98.2%, 100%, and 98.1%, respectively. As a confirmatory assay, the ZIKV RVNT titers displayed 93.1% agreement with the traditional ZIKV PRNT titers. Overall, the RVNT accurately and reliably detects neutralizing antibodies in patient serum specimens, with improved turnaround times, and can be used for the serological detection of ZIKV infections. Due to the homogeneous 96-well format, the RVNT has also significantly improved the assay throughput to allow testing of a large number of specimens in a single run.

Original languageEnglish (US)
Pages (from-to)3028-3036
Number of pages9
JournalJournal of Clinical Microbiology
Volume55
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Neutralization Tests
Dengue Virus
Viruses
Enzyme-Linked Immunosorbent Assay
Zika Virus Infection
Zika Virus
RNA
Antibodies
Clinical Laboratory Techniques
Viremia
Viral RNA
Neutralizing Antibodies
Luciferases
Serum
Immunoglobulin M
Sensitivity and Specificity

Keywords

  • Dengue virus
  • Neutralization assay
  • Sensitivity
  • Specificity
  • Zika virus

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Evaluation of a novel reporter virus neutralization test for serological diagnosis of Zika and Dengue virus infection. / Shan, Chao; Ortiz, Daniel A.; Yang, Yujiao; Wong, Susan J.; Kramer, Laura D.; Shi, Pei-Yong; Loeffelholz, Michael J.; Ren, Ping.

In: Journal of Clinical Microbiology, Vol. 55, No. 10, 01.10.2017, p. 3028-3036.

Research output: Contribution to journalArticle

Shan, Chao ; Ortiz, Daniel A. ; Yang, Yujiao ; Wong, Susan J. ; Kramer, Laura D. ; Shi, Pei-Yong ; Loeffelholz, Michael J. ; Ren, Ping. / Evaluation of a novel reporter virus neutralization test for serological diagnosis of Zika and Dengue virus infection. In: Journal of Clinical Microbiology. 2017 ; Vol. 55, No. 10. pp. 3028-3036.
@article{2616bebb45d04748927e87c1edf8ad78,
title = "Evaluation of a novel reporter virus neutralization test for serological diagnosis of Zika and Dengue virus infection",
abstract = "Currently, the laboratory diagnosis of Zika virus (ZIKV) infection is primarily through the detection of ZIKV RNA or antibodies against ZIKV proteins. The detection of viral RNA is highly sensitive and specific, but periods of viremia and viruria are brief, limiting the utility of ZIKV RNA assays. Instead, most ZIKV infections are diagnosed serologically, using an IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) for screening, followed by a confirmatory plaque reduction neutralization test (PRNT). Typical turnaround times vary, due to assay incubation periods and a lack of clinical laboratories performing these tests. Recently, a novel luciferase-ZIKV-and-dengue virus (DENV)-based serological assay, which considerably improves the turnaround times and throughput for ZIKV diagnosis, was described. Using the traditional PRNT as a reference method, we evaluated the performance characteristics of the reporter virus neutralization test (RVNT) with 258 clinical serum specimens. The ZIKV RVNT produced primary ZIKV screening and secondary confirmation results in 4 days, with 100{\%} reproducibility. As a screening assay, the ZIKV RVNT displayed excellent diagnostic accuracy, sensitivity, and specificity of 98.2{\%}, 100{\%}, and 98.1{\%}, respectively. As a confirmatory assay, the ZIKV RVNT titers displayed 93.1{\%} agreement with the traditional ZIKV PRNT titers. Overall, the RVNT accurately and reliably detects neutralizing antibodies in patient serum specimens, with improved turnaround times, and can be used for the serological detection of ZIKV infections. Due to the homogeneous 96-well format, the RVNT has also significantly improved the assay throughput to allow testing of a large number of specimens in a single run.",
keywords = "Dengue virus, Neutralization assay, Sensitivity, Specificity, Zika virus",
author = "Chao Shan and Ortiz, {Daniel A.} and Yujiao Yang and Wong, {Susan J.} and Kramer, {Laura D.} and Pei-Yong Shi and Loeffelholz, {Michael J.} and Ping Ren",
year = "2017",
month = "10",
day = "1",
doi = "10.1128/JCM.00975-17",
language = "English (US)",
volume = "55",
pages = "3028--3036",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Evaluation of a novel reporter virus neutralization test for serological diagnosis of Zika and Dengue virus infection

AU - Shan, Chao

AU - Ortiz, Daniel A.

AU - Yang, Yujiao

AU - Wong, Susan J.

AU - Kramer, Laura D.

AU - Shi, Pei-Yong

AU - Loeffelholz, Michael J.

AU - Ren, Ping

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Currently, the laboratory diagnosis of Zika virus (ZIKV) infection is primarily through the detection of ZIKV RNA or antibodies against ZIKV proteins. The detection of viral RNA is highly sensitive and specific, but periods of viremia and viruria are brief, limiting the utility of ZIKV RNA assays. Instead, most ZIKV infections are diagnosed serologically, using an IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) for screening, followed by a confirmatory plaque reduction neutralization test (PRNT). Typical turnaround times vary, due to assay incubation periods and a lack of clinical laboratories performing these tests. Recently, a novel luciferase-ZIKV-and-dengue virus (DENV)-based serological assay, which considerably improves the turnaround times and throughput for ZIKV diagnosis, was described. Using the traditional PRNT as a reference method, we evaluated the performance characteristics of the reporter virus neutralization test (RVNT) with 258 clinical serum specimens. The ZIKV RVNT produced primary ZIKV screening and secondary confirmation results in 4 days, with 100% reproducibility. As a screening assay, the ZIKV RVNT displayed excellent diagnostic accuracy, sensitivity, and specificity of 98.2%, 100%, and 98.1%, respectively. As a confirmatory assay, the ZIKV RVNT titers displayed 93.1% agreement with the traditional ZIKV PRNT titers. Overall, the RVNT accurately and reliably detects neutralizing antibodies in patient serum specimens, with improved turnaround times, and can be used for the serological detection of ZIKV infections. Due to the homogeneous 96-well format, the RVNT has also significantly improved the assay throughput to allow testing of a large number of specimens in a single run.

AB - Currently, the laboratory diagnosis of Zika virus (ZIKV) infection is primarily through the detection of ZIKV RNA or antibodies against ZIKV proteins. The detection of viral RNA is highly sensitive and specific, but periods of viremia and viruria are brief, limiting the utility of ZIKV RNA assays. Instead, most ZIKV infections are diagnosed serologically, using an IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) for screening, followed by a confirmatory plaque reduction neutralization test (PRNT). Typical turnaround times vary, due to assay incubation periods and a lack of clinical laboratories performing these tests. Recently, a novel luciferase-ZIKV-and-dengue virus (DENV)-based serological assay, which considerably improves the turnaround times and throughput for ZIKV diagnosis, was described. Using the traditional PRNT as a reference method, we evaluated the performance characteristics of the reporter virus neutralization test (RVNT) with 258 clinical serum specimens. The ZIKV RVNT produced primary ZIKV screening and secondary confirmation results in 4 days, with 100% reproducibility. As a screening assay, the ZIKV RVNT displayed excellent diagnostic accuracy, sensitivity, and specificity of 98.2%, 100%, and 98.1%, respectively. As a confirmatory assay, the ZIKV RVNT titers displayed 93.1% agreement with the traditional ZIKV PRNT titers. Overall, the RVNT accurately and reliably detects neutralizing antibodies in patient serum specimens, with improved turnaround times, and can be used for the serological detection of ZIKV infections. Due to the homogeneous 96-well format, the RVNT has also significantly improved the assay throughput to allow testing of a large number of specimens in a single run.

KW - Dengue virus

KW - Neutralization assay

KW - Sensitivity

KW - Specificity

KW - Zika virus

UR - http://www.scopus.com/inward/record.url?scp=85030091407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030091407&partnerID=8YFLogxK

U2 - 10.1128/JCM.00975-17

DO - 10.1128/JCM.00975-17

M3 - Article

C2 - 28768729

AN - SCOPUS:85030091407

VL - 55

SP - 3028

EP - 3036

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 10

ER -